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WS13.1 The effect of PPI usage on bone health in children with cystic
ﬁbrosis (CF)
M.F. Roddy1,2, B. Elnazir2, P. Greally2. 1AMNCH, Clinical Nutrition and
Dietetics, Dublin, Ireland; 2AMNCH, Cystic Fibrosis Department, Dublin, Ireland
Introduction: The FDA recently issued a broad safety communication regarding
the possible increased risk of osteoporosis-related bone fracture with the use of
PPI’s. PPI’s are regularly used in CF for treatment of GORD and to help with the
efﬁciency of PERT. And as osteoporosis is a co-morbidity of CF we aimed to assess
if there was any relationship between PPI and bone density in children with CF.
Methods: A retrospective review of PPI usage and dxa scans was conducted. Sixty-
four children with mean age of 11 (1.8 SD) were included in study. PPI usage and
duration was recorded. Dxa scans were carried out on the Lunar DPXL-PED. Bone
mineral density (BMD) was recorded and bone mineral apparent density (BMAD)
was calculated. FEV1 was also recorded. Minitab Statistical Package was used to
analyse the data.
Results: Twenty-two (35%) of children were on PPI’s. Duration of use ranged from
1 to 4 years. PPI usage had a marginally signiﬁcant negative effect on BMD [Z score
mean of −0.31 (no PPI) and −0.94 (on PPI), p = 0.05]. PPI had no effect on BMAD
[z score of 0.17 (no PPI) and −0.37 (on PPI), p = 0.08]. The duration of PPI had
no inﬂuence on BMD or BMAD (p = 0.71 and p = 0.51). There was no difference
in FEV1 between the two groups (means of 75% and 76%, p = 0.84).
Conclusion: PPI’s may be prescribed more frequently in sicker patients and thus
could explain the marginal difference found between groups. However this is not
the case here as FEV1 did not differ. Therefore further larger studies are needed in
this area. In the meantime, clinicians should be aware of their potential risk when
considering PPI therapy and should use the lowest effective dose and duration
necessary.
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Introduction: While even recent data conﬁrm that osteopenia and osteoporosis are
very common in adults with cystic ﬁbrosis (CF), no data are available about bone
status in children. Quantitative bone ultrasound (QUS) has been used as a method
to identify reduced bone mineral status in children with disturbance of growth or
disorders affecting bone health. QUS has also been used in adults with CF showing
good speciﬁcity.
Methods:We performed phalangeal quantitative ultrasound examination in patients
with classical CF aged 3 to 6 years and in a group of control. The device used
(DBM Sonic, IGEA, Carpi, Modena, Italy), based on the transmission of ultrasound
through the proximal phalangeal diaphysis calculates raw data and Z-scores for
amplitude-dependent speed of sound (AD-SoS) and bone transmission time (BTT).
Results: We enrolled 30 patients with CF aged 3 to 6 years (15 males, 15 females,
mean age 4.7±1.7 years) and 100 non-CF outpatients (46 males, 54 females, mean
age 4.3±1.8 years) coming to hospital for acute events (mainly acute cough).
AD-SoS value was similar in both CF and control groups (Z-scores −0.1±1.7
and 0.3±1.1, respectively) whereas BTT was signiﬁcantly lower in CF group than
in control group (Z-scores −0.07±0.8 and 0.24±0.7, respectively, p= 0.05).
Conclusion: Although our data need to be supported by larger studies we found
signiﬁcantly lower BTT values in children with cystic ﬁbrosis than in healthy chil-
dren. In the absence of risk factors for osteoporosis such as diabetes, glucocorticoid
use, malnutrition this result may reﬂect the role of CFTR dysfunction on bone tissue
suggesting the need to anticipate the evaluation of bone status in early age.
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Introduction: Reduced BMD is common in adults with CF. Its pathophysiology is
multifactorial. With improved survival early prevention strategies and interventions
to reduce risk factors may alter the natural course of CF-related bone disease.
Aim: To compare the prevalence of osteoporosis and osteopenia (WHO criteria)
and associated risk factors in 2011 to previously published data [1] from the same
centre.
Methods: BMD, clinical and demographic data (age, FEV1, BMI, CFRD, oral
steroid use, transplant status) were collected from electronic patient records
(EMIS®) in 2011 and compared to published data [1] from the same centre (1999).
Results: BMD data from 342 patients in 2011 (median age 28 yrs, FEV1 65% pre-
dicted, BMI 21.9) were compared to 114 patients [1] (age 24.5 yrs, FEV1 47% pre-
dicted, BMI 20.2). 42 patients (12%) in 2011 were post transplantation vs. none in
earlier cohort. No signiﬁcant difference in CFRD or steroid use. The prevalence of
patients with low BMD fell from 66% to 40%, p< 0.001; osteoporosis 18% to 5.8%
(p< 0.001) and osteopenia 48% to 34.5% (p< 0.01). In the earlier cohort low BMD
was signiﬁcantly associated with male gender, disease severity and steroid use. In
2011 the odds ratio of developing low BMD was positively related to male gender
(OR 2.7), disease severity and transplantation (OR 3.0) but not to oral steroid use.
Conclusions: Increased use of bisphosphonates and meticulous attention to nutri-
tion, exercise and endocrine function has resulted in a signiﬁcant reduction in the
prevalence of low BMD. Those remaining most at risk are male patients with severe
disease and those following transplantation.
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Introduction: Compared to the general population, patients with cystic ﬁbrosis (CF)
are known to have lower vitamin D levels secondary to the malabsorption associated
to CF. At our Montreal clinic the supplementation needed to maintain sufﬁcient
25(OH)D levels (75 nmol/L) is doubled during winter months.
Objectives: Characterize 25(OH)D levels among our cohort and compare them
with the 2007–2009 Canadian Health Measures Survey (CHMS).
Methods: Retrospective analysis of the latest data available of 25(OH)D level
among 286 CF adults (53% male, 47% female), 18 to 57 years old (median 29).
Mean BMI (kg/m2) was 23.78 for men and 22.55 for women (p = 0.008). Mean
FEV1 % predicted was 66.88 for men and 64.72 for women.
Results: Mean 25(OH)D value was 79.28 nmol/L (±23.66), women having a
signiﬁcantly higher 25(OH)D (82.41) than men (76.55) (p = 0.037). Compared
to the CHMS (adults data), all of our age-groups had higher 25(OH)D levels:
the 18−39 year old CF group (248 patients) had a mean value of 78.09 nmol/L
compared to the 20−39 year old Canadian group with 65.0 nmol/L. The 40−57 year
old CF group (38 patients) had a mean 25(OH)D serum value of 86.37 nmol/L
compared to 66.5 nmol/L for the Canadian group.
Conclusion: Frequent monitoring of 25(OH)D serum values and Vitamin D3
supplementation increased during winter months, in addition to a close nutrition
follow-up program, probably resulted in superior 25(OH)D serum values in our CF
adult cohort.
